Seronegative Immune-Mediated Necrotizing Myopathy: An Overview for Optimal Clinical Management. (PubMed, Curr Rheumatol Rep) - Oct 4, 2026 - "Immunosuppressive therapy constitutes the cornerstone of treatment, with glucocorticoids as first-line therapy and methotrexate commonly employed as the preferred steroid-sparing agent. Rituximab may be considered in refractory or relapsing disease...Significant gaps persist regarding its pathogenesis, associated comorbidities, and long-term outcomes. This narrative review provides a practical, evidence-based framework for the clinical evaluation and management of patients with seronegative IMNM."
Journal • Review • Musculoskeletal Pain • Myositis • Oncology • Pain • Rheumatology
|
|
Christina Zoubouli; Dimitris C Kounatidis; Eleni Tsaroucha; Maria Dalamaga; Maria Konsta; Natalia G Vallianou; Vasileios Stamatopoulos
|